|
OGT, CCMC announce license agreement
April 2013
SHARING OPTIONS:
OXFORD, United Kingdom—Oxford Gene Technology and the Cancer
Cytogenomics Microarray Consortium (CCMC) have signed a license agreement for
the
creation of a whole-genome, cancer-specific microarray, which includes
probes for more than 500 cancer genes and 130 cancer-associated genomic regions
from the CCMC's design for hematological and solid tumors. The goal is an
improvement in cancer research by enabling accurate identification of DNA
copy
number changes.
"The CCMC license agreement is an endorsement of both OGT's
expertise
in gene-focused arrays and our commitment to developing accurate
solutions for early cancer detection and accurate disease characterization,"
Dr. Mike
Evans, CEO at OGT, said in a press release. "We are proud to be able
to contribute to the good work undertaken by the CCMC to further cancer
research
through increasing access to more comprehensive, accurately
interpreted molecular information."
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|